期刊文献+

平阳霉素-活性炭纳米微粒行口腔癌淋巴化疗的靶向性评价 被引量:13

Lymphatic targeting study of pingyangmycin-activated carbon nanoparticles treating oral cancer lymph node metastasis
下载PDF
导出
摘要 目的观察平阳霉素-活性炭纳米微粒(PYM-CH-NP)经鼠癌周黏膜下给药后,活性药物在体内各组织器官中的分布情况,探讨PYM-CH-NP对淋巴结转移灶的靶向性。方法采用改良氯胺T法将125I标记平阳霉素(PYM),应用淋巴结高转移癌株U14建立昆明小鼠颈淋巴结转移模型。将360只颈淋巴结转移模型小鼠随机分为PYM-CH-NP组、PYM组和阴性对照组,分别于癌周黏膜下注射PYM-CH-NP、PYM水溶液和空白活性炭纳米微粒,给药后0.5、1、4、8、12、24、48、72、96、120、144、168 h处死动物,取血、心、肝、脾、肺、肾和颈淋巴结,检测各时间点各组织器官内平阳霉素的放射活性,计算各样本单位重量的药物放射活性(比放射活性),并计算药物的选择性指数(SI)和靶向指数(TI)。结果 PYM-CH-NP组各时间点颈淋巴结内药物浓度显著高于PYM组(P<0.001),4 h后血、心、肝、脾、肺、肾等器官中药物浓度均低于PYM组(P<0.001)。PYM组各时间点的SI均小于1,而PYM-CH-NP组SI和TI最低值为1.793和1.562,最高为72 h时的68.126和14.623。结论 PYM-CH-NP可显著增加淋巴结转移灶内的药物浓度,同时非靶器官药物分布减少,降低了药物的全身毒副反应。 Objective To investigate the drug distribution in tissues of cervical lymph node metastasis mice model after submucosa adjacent cancer injection of pingyangmycin-activated carbon nanoparticles(PYM-CH-NP) and evaluate the lymph targeting effect of PYM-CH-NP.Methods Pingyangmycin(PYM) was radiolabeled with 125I by modified the chloramine T method.Cervical lymph node metastasis mice model was established by buccal submucosa inoculation of a high lymph metastasis cell line U14 cancer cell.360 mice models burdened with cervical lymph metastasis were ran-domly divided into 3 groups.PYM group was treated with PYM water solution,PYM-CH-NP group was treated with PYM-CH-NP.Negative control group was injected with activated carbon nanoparticles.PYM-CH-NP and pingyangmycin water solution were injected in pericancer submucosa of the mice respectively.The radioactivity of drug in blood,heart,liver,spleen,lung,kidney and cervical lymph node were measured after 0.5,1,4,8,12,24,48,72,96,120,144,168 h administration.The radioactivity of each samples per unit weight were calculated.The selectivity index(SI) and targeting index(TI) of drug were calculated.Results The radioactivity of drug in cervical lymph node of PYM-CH-NP group was much higher than PYM group in each time point(P0.001),whereas the blood,heart,liver,spleen, lung and kidney uptake of pingyangmycin was greatly decreased in PYM-CH-NP group after 4 h administration(P 0.001).The SI value of PYM group at each time point was less than 1.While the minimum SI and TI value of PYM-CH-NP was 1.793 and 1.562,the maxlmum value reached to 68.126 and 14.623 after 72 h administration.Conclusion PYM-CH-NP can increase drug dosage in metastasized cervical lymph nodes,and decrease drug dosage of other organs.So better therapeutic outcome and little adverse reaction may be achieved for lymph node metastasis.
出处 《华西口腔医学杂志》 CAS CSCD 北大核心 2011年第3期253-256,263,共5页 West China Journal of Stomatology
基金 卫生部科学研究基金资助项目(98-1-221)
关键词 活性炭 纳米微粒 平阳霉素 淋巴结转移 靶向治疗 activated carbon nanoparticle pingyangmycin lymph node metastasis targeted therapy
  • 相关文献

参考文献7

  • 1孙明磊,王昌美,温玉明.平阳霉素-活性炭纳米微粒对口腔鳞癌细胞系Tca8113和BcaCD885细胞体外的杀伤作用[J].华西口腔医学杂志,2010,28(3):257-260. 被引量:4
  • 2Xie Y, Bagby TR, Cohen MS, et al. Drug delivery to the lymphatic system: Importance in future cancer diagnosis and therapies[J]. Expert Opin Drug Deliv, 2009, 6(8):785-792.
  • 3Galagudza MM, Korolev DV, Sonin DL, et al. Targeted drug deli- very into reversibly injured myoeardium with silica nanopartieles: Surface functionalizatiors natural biodistribution, and acute toxicity [J]. Int J Nanomedicine, 2010, 5:231-237.
  • 4Lindner LH, Hossarm M. Factors affecting drug release from lipo- somes[J]. Curr Opin Drug Discov Devel, 2010, 13(1):111-123.
  • 5Lamprecht A, Yamamoto H, Takeuchi H, et al. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats[J]. J Pharmacol Exp Ther, 2005,315 (1) : 196-202.
  • 6杨凯,陈绍维,陈睿,温玉明.隐形顺铂聚乳酸纳米微粒对口腔鳞癌原发灶的靶向性研究[J].华西口腔医学杂志,2005,23(5):445-448. 被引量:9
  • 7Phillips WT, Klipper R, Coins B. Novel method of greatly enhan- ced delivery of liposomes to lymph nodes[J]. J Pharmacol Exp Ther, 2000, 295(1) :309-313.

二级参考文献19

  • 1孙明磊,温玉明,王昌美,李龙江,王晓毅.淋巴靶向平阳霉素—活性炭纳米微粒的研制[J].华西口腔医学杂志,2004,22(3):183-185. 被引量:10
  • 2李龙江,温玉明,王昌美.颊癌微血管分支类型的动物实验研究[J].华西口腔医学杂志,1996,14(2):79-82. 被引量:3
  • 3Byrue JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics[J]. Adv Drug Deliv Rev, 2008, 60(15): 1615-1626.
  • 4Hughes GA. Nanostructure-mediated drug delivery[J]. Dis Mon, 2005, 51 (6) : 342-361.
  • 5Ademuyiwa FO, Miller KD. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer[J], Clin Breast Cancer, 2008, 8 (Suppl 4) :S151-S156.
  • 6Leamon CP, Reddy JA. Folate-targeted chemotherapy[J]. Adv Drug Deliv Rev, 2004, 56(8):1127-1141.
  • 7Ito T, Hagiwara A, Takagi T, et al. Local administration of methotrexate bound to activated carbon particles (MTX-CH) for treating cancers in mice[J]. Anticancer Res, 2003, 23 (2B):1401- 1404.
  • 8Peracchia MT, Fattal E, Desmaele D, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting[J]. J Control Release, 1999, 60(1):121-128.
  • 9Gref R,Quellec P, Sanchez A, et al. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol) PEG micro-and nanoparticles, comparison with conventional PLA particulate carriers[J]. Eur J Pharm and Biopharm, 2000,51(2): 111-118.
  • 10Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size[J]. Cancer Res, 1995,55(17):3752-3756.

共引文献11

同被引文献182

引证文献13

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部